Test Price
2,800 AED✅ Home Collection Available
ZBTB24 Gene ICF Syndrome Type 2 Genetic Test in UAE | 2800 AED | DHA Approved
Executive Summary & Core Metrics
- 99.9% analytical sensitivity via next-generation sequencing (NGS) under ISO 9001:2015 certified processes.
- VIP Mobile Phlebotomy & temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.
- Post-test teleconsultation for clinical interpretation and management guidance.
- Direct insurance coverage verification via WhatsApp +971545488731.
Test Overview & Methodology
This advanced next-generation sequencing (NGS) test examines the ZBTB24 gene for pathogenic variants causing Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome Type 2 (ICF2), a rare autosomal recessive disorder. Results are typically available within 3–4 weeks at a cost of 2,800 AED with full compliance with Dubai Health Authority regulations.
| Parameter | Our Test (NGS) | Targeted Sanger Sequencing |
|---|---|---|
| Precision | 99.9% analytical sensitivity, full gene coverage | ~95% sensitivity, limited to known mutations |
| Method | Next‑Generation Sequencing (Illumina® platform) | Sanger capillary electrophoresis |
| Speed | 3–4 weeks | 4–6 weeks |
| Variant Detection | SNVs, indels, copy number variants | SNVs and small indels only |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I emphasize that genetic test results must be interpreted within the context of a comprehensive clinical evaluation and family history. This NGS test provides definitive diagnostic clarity for families facing a rare and complex syndrome, enabling early immunologic intervention and targeted surveillance.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Safety Advisory
Do not discontinue prescribed medication without consulting your doctor. Abrupt discontinuation can exacerbate underlying immunodeficiency.
Exclusion Criteria & Emergency Red Flags
- Acute febrile illness or active severe infection requiring immediate hospitalization.
- Inability to provide informed consent (for minors, guardian consent mandated per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Severe worsening of facial anomalies causing airway compromise – seek emergency care.
- Signs of overwhelming sepsis: high fever, breathing difficulty, confusion – go to ER immediately.
- Uncontrolled bleeding or sudden severe bruising – call emergency services.
Patient FAQ & Clinical Guidance
1. What is the ZBTB24 gene test used for?
This NGS test confirms ICF syndrome type 2 by detecting pathogenic variants in the ZBTB24 gene with >99% sensitivity. It is indicated for children and adults presenting with recurrent infections, distinct facial features, and chromosomal instability findings.
2. How should I prepare for the test?
A genetic counseling session is required to draw a pedigree of affected family members and obtain informed consent before sample collection. The sample can be whole blood, extracted DNA, or one drop of blood on an FTA card; fasting is not needed.
3. What are the limitations and risks of this genetic test?
The test may not detect deep intronic variants, large chromosomal rearrangements, or mosaic variants; results require clinical correlation with immunology and dysmorphology assessments. There is no physical risk beyond routine venipuncture, and data is protected under UAE PDPL.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance
We strictly adhere to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your sample and data are processed under ISO 9001:2015 certified protocols (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | ZBTB24 Gene ICF Syndrome Type 2 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood, extracted DNA, or FTA card (VIP Mobile Phlebotomy & cold-chain home collection available) |
| Methodology Used | Next-Generation Sequencing (NGS) on Illumina® platform |
| ICD-10-CM Code | D82.8 (Other immunodeficiency with predominantly antibody defects) |
| LOINC Code | 81247-9 (ZBTB24 gene mutation analysis) |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE Corporate Lab Branding: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians